I Szelenyi

Summary

Affiliation: University of Erlangen-Nuremberg
Country: Germany

Publications

  1. doi request reprint Flupirtine, a re-discovered drug, revisited
    Istvan Szelenyi
    Institute for Experimental and Clinical Pharmacology and Toxicology, Doerenkamp Chair for Innovations in Animal and Consumer Protection, Friedrich Alexander University, Fahrstrasse 17, 91054 Erlangen, Germany
    Inflamm Res 62:251-8. 2013
  2. ncbi request reprint Soft drugs for future treatment of chronic obstructive pulmonary disease (COPD)
    I Szelenyi
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University, Erlangen, Germany
    Pharmazie 67:371-3. 2012
  3. doi request reprint Nanomedicine: evolutionary and revolutionary developments in the treatment of certain inflammatory diseases
    Istvan Szelenyi
    Doerenkamp Lehrstuhl für Innovationen im Tier und Verbraucherschutz, Institut fur Experimentelle und Klinische Pharmakologie und Toxikologie, Friedrich Alexander Universitat Erlangen Nurnberg, Erlangen, Germany
    Inflamm Res 61:1-9. 2012
  4. ncbi request reprint Herbal remedies for asthma treatment: between myth and reality
    Istvan Szelenyi
    Department of Pulmonary Pharmacology, Corporate Research and Development, ASTA Medica AG, Radebeul, Germany
    Drugs Today (Barc) 38:265-303. 2002
  5. ncbi request reprint Animal models of chronic obstructive pulmonary disease
    I Szelenyi
    Department Pulmonary Pharmacology, Corporate Research and Development, ASTA Medica AG, Radebeul, Germany
    Arzneimittelforschung 51:1004-14. 2001
  6. ncbi request reprint Asthma therapy in the new millennium
    A Pahl
    Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University of Erlangen, Germany
    Inflamm Res 51:273-82. 2002
  7. ncbi request reprint Animal models of allergic rhinitis
    I Szelenyi
    Department Pulmonary Pharmacology, Corporate Research and Development, ASTA Medica AG, Radebeul and Halle Künsebeck, Germany
    Arzneimittelforschung 50:1037-42. 2000
  8. ncbi request reprint Drug therapy in asthma bronchiale in the new millennium
    I Szelenyi
    ASTA Medica AG, Radebeul, Germany
    Pharmazie 57:83-6. 2002
  9. ncbi request reprint Anti-inflammatory effects of a cyclosporine receptor-binding compound, D-43787
    Andreas Pahl
    Department of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen Nurnberg, Erlangen, Germany
    J Pharmacol Exp Ther 301:738-46. 2002
  10. pmc Regulation of IL-13 synthesis in human lymphocytes: implications for asthma therapy
    Andreas Pahl
    Department of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen Nurnberg, Fahrstr 17, D 91054 Erlangen, Germany
    Br J Pharmacol 135:1915-26. 2002

Detail Information

Publications13

  1. doi request reprint Flupirtine, a re-discovered drug, revisited
    Istvan Szelenyi
    Institute for Experimental and Clinical Pharmacology and Toxicology, Doerenkamp Chair for Innovations in Animal and Consumer Protection, Friedrich Alexander University, Fahrstrasse 17, 91054 Erlangen, Germany
    Inflamm Res 62:251-8. 2013
    ..One of them has now been realized: its back-up compound, the bioisostere retigabine, has been approved for the treatment of epilepsy...
  2. ncbi request reprint Soft drugs for future treatment of chronic obstructive pulmonary disease (COPD)
    I Szelenyi
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University, Erlangen, Germany
    Pharmazie 67:371-3. 2012
    ..Advances in understanding the pathogenesis of COPD have the potential for identifying new therapeutic targets. Additionally, forgotten old compounds might undergo a revival by means of novel pharmaceutical technology...
  3. doi request reprint Nanomedicine: evolutionary and revolutionary developments in the treatment of certain inflammatory diseases
    Istvan Szelenyi
    Doerenkamp Lehrstuhl für Innovationen im Tier und Verbraucherschutz, Institut fur Experimentelle und Klinische Pharmakologie und Toxikologie, Friedrich Alexander Universitat Erlangen Nurnberg, Erlangen, Germany
    Inflamm Res 61:1-9. 2012
    ..It is hard to predict what precise course nanomedicine will take in years to come. It is, however, very likely that this relatively young research area will become a driving force behind a vast revolution in medical treatment...
  4. ncbi request reprint Herbal remedies for asthma treatment: between myth and reality
    Istvan Szelenyi
    Department of Pulmonary Pharmacology, Corporate Research and Development, ASTA Medica AG, Radebeul, Germany
    Drugs Today (Barc) 38:265-303. 2002
    ..The present review evaluates herbs and their efficacy in asthma to provide a balanced and objective view for the reader seeking information on herbal therapy..
  5. ncbi request reprint Animal models of chronic obstructive pulmonary disease
    I Szelenyi
    Department Pulmonary Pharmacology, Corporate Research and Development, ASTA Medica AG, Radebeul, Germany
    Arzneimittelforschung 51:1004-14. 2001
    ..For this reason, a wide variety of animal models have been developed and are employed in the search for new chemical entities for the treatment of COPD. In the present paper, the experimental models of COPD are critically reviewed...
  6. ncbi request reprint Asthma therapy in the new millennium
    A Pahl
    Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University of Erlangen, Germany
    Inflamm Res 51:273-82. 2002
    ..Today's intensive search for new treatments should ensure a greater diversity of therapeutic possibilities for the management of asthma in the next millennium...
  7. ncbi request reprint Animal models of allergic rhinitis
    I Szelenyi
    Department Pulmonary Pharmacology, Corporate Research and Development, ASTA Medica AG, Radebeul and Halle Künsebeck, Germany
    Arzneimittelforschung 50:1037-42. 2000
    ..In the present review, advantages and disadvantages of experimental methods of rhinitis will be discussed...
  8. ncbi request reprint Drug therapy in asthma bronchiale in the new millennium
    I Szelenyi
    ASTA Medica AG, Radebeul, Germany
    Pharmazie 57:83-6. 2002
    ..Today's intensive search for new treatments should ensure a greater diversity of therapeutic possibilities for the management of asthma in the new millennium...
  9. ncbi request reprint Anti-inflammatory effects of a cyclosporine receptor-binding compound, D-43787
    Andreas Pahl
    Department of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen Nurnberg, Erlangen, Germany
    J Pharmacol Exp Ther 301:738-46. 2002
    ..In conclusion, we characterized a novel Th2 selective immunosuppressive drug with possible anti-asthmatic/anti-inflammatory effects. Its mode of action is distinct from that of CsA...
  10. pmc Regulation of IL-13 synthesis in human lymphocytes: implications for asthma therapy
    Andreas Pahl
    Department of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen Nurnberg, Fahrstr 17, D 91054 Erlangen, Germany
    Br J Pharmacol 135:1915-26. 2002
    ..Characterizing highly potent inhibitors of IL-13 synthesis can be exploited to identify new drugs to treat immunological diseases such as asthma...
  11. pmc Bioavailability of diclofenac potassium at low doses
    Burkhard Hinz
    Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen Nurnberg, Fahrstrasse 17, D 91054 Erlangen, Germany
    Br J Clin Pharmacol 59:80-4. 2005
    ..However, given the considerable first-pass metabolism of diclofenac, the degree of absorption of diclofenac-K at low doses remained to be determined. The aim of this study was to determine the bioavailability of low-dose diclofenac-K...
  12. ncbi request reprint Is asthma research in dead end?
    Annette Amon
    Department of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen, Fahrstr 17, 91054 Erlangen, Germany
    Exp Toxicol Pathol 57:45-7. 2006
    ..The present drug screening strategy should be reconsidered and probably be replaced by new and more serendipity-based research...
  13. ncbi request reprint Are there any realistic chances to develop new drugs for asthma?
    Annette Amon
    Department of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen, Erlangen, Germany
    Drug News Perspect 19:189-200. 2006
    ..With these imperatives in mind, we can hope to better manage this multifactor disease in the near future...